Obese Zucker rats treated with AOD-9604 at 500 mcg/kg/day for 19 days showed a statistically significant reduction in body fat compared to vehicle-treated controls
Signs You May Have a B12 Deficiency B12 deficiency can cause a variety of symptoms, including fatigue, headaches, depression, pale or yellow skin, mental impairment, and pain and inflammation of the mouth and tongue
Secretary Kennedy has made no secret of his support for the molecules, saying he has used some of them himself and would like the FDA which is overseen by the Department of Health and Human Services to allow compounding pharmacies to again offer the drugs
Approaches like that might hold the answer for detecting peptides better in the future

Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome

You can get one from your doctor